Non-small cell lung cancer

Description
Available tests: Fluorescence in situ hybridisation analysis of FFPE tissue sections for: ALK t(2p23;) rearrangement; ROS1 t(6q22;) rearrangement; MET (7q31) copy number/ratio; RET t(10q11;) rearrangement
Clinical details
The determination of ALK status in patients with lung cancer is critical in the identification of patients eligible for ALK inhibitor therapy. Patients with ROS1 rearrangement have also been shown to be sensitive to the ALK inhibitor crizotininb, MET amplification may contribute to acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI's), and may be a target for MET inhibitors. Patients showing rearrangement of RET have been shown to benefit from treatment with RET tyrosine kinase inhibitors.
Synonyms
ALK, ROS1, MET, RET, crizotininb, Xalkori, lung cancer, non-small cell lung cancer, adenocarcinoma, NSCLC
Testing site
Synnovis : Genomics : Guy's Hospital
Laboratory
Cancer Genetics
Sample type and volume required
FFPE tissue sections - 3-4µm sections on unstained Apes slides with appropriate IHC/H&E slide for correlation
Turnaround time
Current service turnaround times: Urgent 2-7 calendar days; Non-urgent 5-10 calendar days; National targets: Urgent samples 95% reported within 14 days; Non-urgent 95% reprted within 21 days

Last updated:

Back to search